Astellas to conduct multicenter Asian trial of Factor Xa inhibitor - YM150
Japan's Astellas Pharma, the country's second largest drugmaker by sales, has announced that it will undertake an international Phase II clinical trial of its developmental activated Factor Xa inhibitor YM150, at sites in Hong Kong, South Korea and Taiwan.
The firm said that, in targeting activated Factor Xa, a blood factor that is key to the coagulation cascade, YM150 has potential as a treatment for a wide range of thrombotic indications. The company added that the drug is currently under assessment in a Phase II clinical trial in Japan, and a Phase IIb study in Europe, as a therapy for venous thromboembolism.
In addition, Astellas said that it is making preparations for Phase II trials of the drug as a treatment for atrial fibrillation in Europe and the USA, which are scheduled to start in the current fiscal year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze